Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors
Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on c...
Saved in:
| Published in | Retrovirology Vol. 11; no. 1; p. 36 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
19.05.2014
BioMed Central |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined.
We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues.
We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. |
|---|---|
| AbstractList | Doc number: 36 Abstract Background: Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined. Results: We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues. Conclusions: We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined. We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues. We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. Background Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined. Results We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues. Conclusions We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. Keywords: Gamma-retrovirus, Insertional mutagenesis, Oncogenesis, Deep sequencing, Chromatin immunoprecipication with sequencing (ChIP-seq), Retroviral integration sites, RNA sequencing (RNA-seq) Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined. We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues. We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. Background: Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined. Results: We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues. Conclusions: We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined.BACKGROUNDInsertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to individual retroviral integration sites has been based on close proximity and expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived from end-stage tumors of more than 2,000 mice was examined.We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues.RESULTSWe detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine lymphoid tissues.We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology.CONCLUSIONSWe expose novel retrovirus-induced host transcription activation patterns that reach beyond a single and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular regulatory principles and retroviral biology. |
| ArticleNumber | 36 |
| Audience | Academic |
| Author | Ruiz, Irene Rius Pedersen, Finn Skou Wabl, Matthias Sokol, Martin |
| AuthorAffiliation | 1 Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark 2 Department of Microbiology and Immunology, University of California, San Francisco, CA 94143, USA |
| AuthorAffiliation_xml | – name: 1 Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark – name: 2 Department of Microbiology and Immunology, University of California, San Francisco, CA 94143, USA |
| Author_xml | – sequence: 1 givenname: Martin surname: Sokol fullname: Sokol, Martin – sequence: 2 givenname: Matthias surname: Wabl fullname: Wabl, Matthias – sequence: 3 givenname: Irene Rius surname: Ruiz fullname: Ruiz, Irene Rius – sequence: 4 givenname: Finn Skou surname: Pedersen fullname: Pedersen, Finn Skou |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24886479$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktv1DAUhS1URNuBNTtkiQ2btH4lsTdIVcVLqmADa8uxbwYXxx7sZKSKP49n-qCtQEJe5Nr-zlF87zlGBzFFQOglJSeUyu6U9oI1olOkobTh3RN0dHdycK8-RMelXBLCqSTyGTpkQspO9OoI_fqcthDwJvto_SZAwWnEazNNpskw57T12QTsY4E8-xRrPWcTi81-s9tjY2e_NfvSRzwt1QdwgOUHTN7gql5K46NbLDgM0TVlNmvA8zKlXJ6jp6MJBV7cfFfo2_t3X88_NhdfPnw6P7tobMvo3NhRDZ1rmSF2UMaNAyGjoMIy3jMQxDoFAzjSMcVoRx1jykpuuAEzypbLga_Q22vfzTJM4CzE-oag65snk690Ml4_vIn-u16nrRZEyV6JavDmxiCnnwuUWU--WAjBREhL0bTlQvK-F_3_oEwJJuosVuj1I_QyLbm2eE8pJlvK2B9qbQJoH8dUf9HuTPVZpbqeEiYrdfIXqi5X52BrZkZfzx8IXt3vyV0zbpNRgfYasDmVkmHU1s_7QVdnHzQlepdAvcuY3mWsbjXvqu70ke7W-l-K3xxF3lU |
| CitedBy_id | crossref_primary_10_1002_eji_201445218 crossref_primary_10_1186_s12977_015_0161_9 crossref_primary_10_1038_ncomms15264 crossref_primary_10_3390_v6124811 crossref_primary_10_1111_apm_12477 crossref_primary_10_1007_s40124_014_0069_1 crossref_primary_10_1128_spectrum_01478_22 crossref_primary_10_1038_s41467_021_21612_7 crossref_primary_10_1002_eji_201344322 crossref_primary_10_31857_S0320972524040051 crossref_primary_10_3390_v14020445 crossref_primary_10_1134_S0006297924040059 crossref_primary_10_1099_jgv_0_000271 crossref_primary_10_1128_JVI_01127_16 crossref_primary_10_7554_eLife_36245 crossref_primary_10_1186_s12977_023_00622_x crossref_primary_10_1186_s13062_015_0097_y |
| Cites_doi | 10.1182/blood-2007-01-068478 10.1111/j.1365-2141.2008.07453.x 10.4048/jbc.2007.10.3.180 10.1371/journal.pone.0055721 10.1056/NEJMoa012616 10.1016/0092-8674(84)90309-X 10.1172/JCI35798 10.1126/science.1164266 10.1101/gr.092833.109 10.1073/pnas.82.2.459 10.1038/sj.onc.1209043 10.1101/gr.078519.108 10.1016/j.gene.2009.04.003 10.1038/nm.2088 10.1146/annurev.genom.7.080505.115623 10.1371/journal.pone.0027770 10.1186/1752-0509-4-163 10.1038/nature11279 10.1038/nprot.2009.64 10.1093/nar/gkh013 10.1093/bioinformatics/btp120 10.1093/bioinformatics/btq033 10.1371/journal.pone.0024247 10.1093/hmg/ddg180 10.1093/nar/gks1182 10.1186/gb-2013-14-10-r117 10.1016/j.meegid.2012.05.001 10.1093/nar/23.9.1644 10.1182/blood-2010-05-283523 10.1038/onc.2011.99 10.1128/jvi.69.1.446-455.1995 10.1038/nature07943 10.1086/341527 10.1186/1742-4690-4-5 10.1038/nbt.1526 10.1128/JVI.01077-12 10.1038/ng.368 10.1101/gad.13.19.2465 10.1073/pnas.1016071107 10.1089/hgtb.2011.219 10.1023/A:1012265703669 10.1016/j.cell.2012.04.041 10.1038/nm1393 10.1016/j.ymeth.2010.04.004 10.1038/ki.2010.176 10.1128/JVI.02088-09 10.1371/journal.pcbi.1001008 10.1016/0042-6822(84)90146-6 10.1016/j.leukres.2013.04.012 10.1016/j.coi.2012.08.006 10.1089/hum.2012.203 10.1126/science.1083413 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5 10.1038/bjc.2013.233 10.1128/jvi.60.2.683-692.1986 10.1016/j.mehy.2007.03.029 10.1038/nature11243 10.1016/S0140-6736(04)17590-9 10.1093/nar/gkt1399 10.1006/geno.1999.5952 10.1016/j.cell.2011.01.024 10.1172/JCI62189 10.1038/292167a0 10.3390/v3050429 10.1182/blood-2012-02-409839 10.1371/journal.pgen.1000491 10.1093/bioinformatics/btp324 10.1016/j.celrep.2013.09.040 10.1371/journal.pone.0073974 10.1128/JVI.00427-09 10.1038/ng950 10.1073/pnas.1307157110 10.1002/emmm.201000108 10.1093/hmg/ddp409 10.1186/gb-2013-14-9-r106 10.1128/JVI.00252-11 10.2174/1566523211313030006 10.1101/gr.229202. Article published online before March 2002 10.1038/nprot.2012.016 10.1073/pnas.1004139107 10.1126/science.288.5466.669 10.1128/mBio.00134-11 10.1101/gr.149674.112 10.1126/science.1088547 10.1242/dev.01613 10.3892/ijmm.2013.1314 10.1093/nar/gkr719 10.1006/geno.2001.6558 10.1016/j.tig.2011.04.002 10.7178/ig.1.1.7 10.1128/JVI.00635-11 10.1186/1742-4690-5-4 10.1128/JVI.73.9.7599-7606.1999 10.1097/NEN.0b013e31826bf704 10.1038/nrg2957 10.1128/JVI.00011-14 10.1101/gr.112763.110 10.1073/pnas.0609030103 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2014 BioMed Central Ltd. 2014 Sokol et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Copyright © 2014 Sokol et al.; licensee BioMed Central Ltd. 2014 Sokol et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2014 BioMed Central Ltd. – notice: 2014 Sokol et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. – notice: Copyright © 2014 Sokol et al.; licensee BioMed Central Ltd. 2014 Sokol et al.; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1186/1742-4690-11-36 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1742-4690 |
| EndPage | 36 |
| ExternalDocumentID | PMC4098794 3346358731 A539671028 24886479 10_1186_1742_4690_11_36 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI041570 |
| GroupedDBID | --- 0R~ 123 29P 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7U9 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c521t-cf9b6d52a0cb9adfb00f414c2372e40cd9ebed06292161d229c83a3aeaf8538b3 |
| IEDL.DBID | M48 |
| ISSN | 1742-4690 |
| IngestDate | Thu Aug 21 14:05:01 EDT 2025 Fri Jul 11 05:32:08 EDT 2025 Thu Jul 10 23:35:55 EDT 2025 Fri Jul 25 06:56:13 EDT 2025 Tue Jun 17 21:28:25 EDT 2025 Tue Jun 10 20:11:11 EDT 2025 Mon Jul 21 05:20:09 EDT 2025 Thu Apr 24 23:03:12 EDT 2025 Tue Jul 01 03:39:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-cf9b6d52a0cb9adfb00f414c2372e40cd9ebed06292161d229c83a3aeaf8538b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.proquest.com/docview/1539285122?pq-origsite=%requestingapplication% |
| PMID | 24886479 |
| PQID | 1539285122 |
| PQPubID | 54665 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4098794 proquest_miscellaneous_1534837747 proquest_miscellaneous_1532942400 proquest_journals_1539285122 gale_infotracmisc_A539671028 gale_infotracacademiconefile_A539671028 pubmed_primary_24886479 crossref_citationtrail_10_1186_1742_4690_11_36 crossref_primary_10_1186_1742_4690_11_36 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-05-19 |
| PublicationDateYYYYMMDD | 2014-05-19 |
| PublicationDate_xml | – month: 05 year: 2014 text: 2014-05-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Retrovirology |
| PublicationTitleAlternate | Retrovirology |
| PublicationYear | 2014 |
| Publisher | BioMed Central Ltd BioMed Central |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
| References | HT Cuypers (3890_CR70) 1984; 37 RS Devon (3890_CR38) 1995; 23 C Trapnell (3890_CR47) 2012; 7 Y Yang (3890_CR83) 1999; 62 MJ Zeitz (3890_CR91) 2013; 8 EF Hays (3890_CR1) 1984; 138 MH Rasmussen (3890_CR54) 2010; 84 UP Dave (3890_CR71) 2009; 5 AG Robertson (3890_CR65) 2008; 18 HB Gaspar (3890_CR10) 2004; 364 GC Hon (3890_CR63) 2009; 18 Y Shen (3890_CR25) 2012; 488 LA Lettice (3890_CR33) 2003; 12 A Sanyal (3890_CR57) 2012; 489 LH Evans (3890_CR69) 1985; 82 S Ingvarsson (3890_CR85) 2005; 2 D Li (3890_CR62) 2001; 74 SJ Howe (3890_CR13) 2008; 118 X Wu (3890_CR17) 2003; 300 AM Lum (3890_CR50) 2007; 4 W Wei (3890_CR59) 2011; 27 J Zhang (3890_CR35) 2012; 86 H Dong (3890_CR58) 2010; 4 M Bulger (3890_CR64) 1999; 13 T Sagai (3890_CR34) 2005; 132 CL Wang (3890_CR49) 2006; 103 H Mikkers (3890_CR36) 2002; 32 A Nowrouzi (3890_CR4) 2011; 3 VW Keng (3890_CR66) 2009; 27 S Hacein-Bey-Abina (3890_CR72) 2003; 302 FS Pedersen (3890_CR2) 1981; 292 S Hacein-Bey-Abina (3890_CR11) 2002; 346 AR Quinlan (3890_CR53) 2010; 26 BV North (3890_CR101) 2002; 71 LG Schuettpelz (3890_CR78) 2012; 120 C Flotho (3890_CR77) 2007; 110 R Gabriel (3890_CR6) 2012; 24 ST Chang (3890_CR46) 2011; 2 A Gonzalez-Perez (3890_CR90) 2013; 14 W Pi (3890_CR98) 2010; 107 J Qu (3890_CR86) 2013; 31 NC Schopman (3890_CR42) 2012; 40 S Knight (3890_CR3) 2013; 13 D Cesana (3890_CR44) 2012; 122 MG Ott (3890_CR15) 2006; 12 A Ciuffi (3890_CR40) 2011; 53 M Cavazzana-Calvo (3890_CR12) 2000; 288 MR Stratton (3890_CR75) 2009; 458 KS Park (3890_CR79) 2007; 10 WJ Kent (3890_CR99) 2002; 12 S Stein (3890_CR14) 2010; 16 G Lefebvre (3890_CR43) 2011; 85 I Kholodnyuk (3890_CR84) 1997; 18 MJ Martiney (3890_CR67) 1999; 73 R Kikuchi (3890_CR55) 2010; 78 K Karrman (3890_CR61) 2009; 144 A Sharma (3890_CR29) 2013; 110 A Cavazza (3890_CR5) 2013; 24 SW Cheetham (3890_CR94) 2013; 108 H Mikkers (3890_CR9) 2003; 88 CG Mullighan (3890_CR74) 2008; 322 L Hong (3890_CR88) 2007; 69 L Biasco (3890_CR20) 2011; 3 MJ Dabrowska (3890_CR52) 2013; 37 L Taher (3890_CR31) 2013; 14 MJ Koudijs (3890_CR45) 2011; 21 B Zhang (3890_CR27) 2013; 23 U Abel (3890_CR73) 2011; 6 E Perez-Magan (3890_CR82) 2012; 71 GA Maston (3890_CR32) 2006; 7 AG Uren (3890_CR8) 2005; 24 S Kalyana-Sundaram (3890_CR93) 2012; 149 A Arens (3890_CR41) 2012; 23 GJ Faulkner (3890_CR97) 2009; 41 M Bulger (3890_CR96) 2011; 144 SS De Ravin (3890_CR24) 2014; 88 A Torkamani (3890_CR76) 2009; 19 MC Lafave (3890_CR22) 2014; 42 D Karolchik (3890_CR89) 2011; Chapter 18 MJ Dabrowska (3890_CR7) 2009; 83 C Cattoglio (3890_CR18) 2010; 116 C-T Ong (3890_CR95) 2011; 12 D Ustek (3890_CR39) 2012; 12 S Vijaya (3890_CR16) 1986; 60 PA Masso-Welch (3890_CR81) 2001; 68 S Messina (3890_CR87) 2011; 30 J De Rijck (3890_CR30) 2013; 5 SL Roth (3890_CR19) 2011; 85 AS Orekhova (3890_CR92) 2013; 78 GB Beck-Engeser (3890_CR48) 2008; 5 K Akagi (3890_CR51) 2004; 32 Y Tian (3890_CR28) 2011; 6 AG Uren (3890_CR37) 2009; 4 B Eun (3890_CR56) 2013; 41 H Li (3890_CR100) 2009; 25 FA Santoni (3890_CR23) 2010; 6 C Trapnell (3890_CR102) 2009; 25 A Moiani (3890_CR21) 2013; 8 S Ramalingam (3890_CR80) 2012; 1 MP Creyghton (3890_CR26) 2010; 107 AA Nielsen (3890_CR60) 2009; 442 HL Morrison (3890_CR68) 1995; 69 |
| References_xml | – volume: 110 start-page: 1271 issue: 4 year: 2007 ident: 3890_CR77 publication-title: Blood doi: 10.1182/blood-2007-01-068478 – volume: 144 start-page: 546 issue: 4 year: 2009 ident: 3890_CR61 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2008.07453.x – volume: 10 start-page: 180 issue: 3 year: 2007 ident: 3890_CR79 publication-title: J Breast Cancer doi: 10.4048/jbc.2007.10.3.180 – volume: 8 start-page: e55721 issue: 1 year: 2013 ident: 3890_CR21 publication-title: PLoS One doi: 10.1371/journal.pone.0055721 – volume: 346 start-page: 1185 issue: 16 year: 2002 ident: 3890_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa012616 – volume: 37 start-page: 141 issue: 1 year: 1984 ident: 3890_CR70 publication-title: Cell doi: 10.1016/0092-8674(84)90309-X – volume: 118 start-page: 3143 issue: 9 year: 2008 ident: 3890_CR13 publication-title: J Clin Invest doi: 10.1172/JCI35798 – volume: 322 start-page: 1377 issue: 5906 year: 2008 ident: 3890_CR74 publication-title: Science doi: 10.1126/science.1164266 – volume: 19 start-page: 1570 issue: 9 year: 2009 ident: 3890_CR76 publication-title: Genome Res doi: 10.1101/gr.092833.109 – volume: 82 start-page: 459 issue: 2 year: 1985 ident: 3890_CR69 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.82.2.459 – volume: 24 start-page: 7656 issue: 52 year: 2005 ident: 3890_CR8 publication-title: Oncogene doi: 10.1038/sj.onc.1209043 – volume: 18 start-page: 1906 issue: 12 year: 2008 ident: 3890_CR65 publication-title: Genome Res doi: 10.1101/gr.078519.108 – volume: 442 start-page: 55 issue: 1–2 year: 2009 ident: 3890_CR60 publication-title: Gene doi: 10.1016/j.gene.2009.04.003 – volume: 16 start-page: 198 issue: 2 year: 2010 ident: 3890_CR14 publication-title: Nature medicine doi: 10.1038/nm.2088 – volume: 7 start-page: 29 year: 2006 ident: 3890_CR32 publication-title: Annu Rev Genomics Hum Genet doi: 10.1146/annurev.genom.7.080505.115623 – volume: 2 start-page: 247 issue: 4 year: 2005 ident: 3890_CR85 publication-title: Cancer Genomics Proteomi – volume: 6 start-page: e27770 issue: 11 year: 2011 ident: 3890_CR28 publication-title: PLoS One doi: 10.1371/journal.pone.0027770 – volume: 4 start-page: 163 year: 2010 ident: 3890_CR58 publication-title: BMC Syst Biol doi: 10.1186/1752-0509-4-163 – volume: 489 start-page: 109 issue: 7414 year: 2012 ident: 3890_CR57 publication-title: Nature doi: 10.1038/nature11279 – volume: 4 start-page: 789 issue: 5 year: 2009 ident: 3890_CR37 publication-title: Nat Protoc doi: 10.1038/nprot.2009.64 – volume: 32 start-page: D523 issue: Database issue year: 2004 ident: 3890_CR51 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkh013 – volume: 25 start-page: 1105 issue: 9 year: 2009 ident: 3890_CR102 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp120 – volume: 26 start-page: 841 issue: 6 year: 2010 ident: 3890_CR53 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq033 – volume: 6 start-page: e24247 issue: 10 year: 2011 ident: 3890_CR73 publication-title: PLoS One doi: 10.1371/journal.pone.0024247 – volume: 88 start-page: 53 year: 2003 ident: 3890_CR9 publication-title: Adv Cancer Res – volume: 12 start-page: 1725 issue: 14 year: 2003 ident: 3890_CR33 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddg180 – volume: 41 start-page: 817 issue: 2 year: 2013 ident: 3890_CR56 publication-title: Nucleic Acids Res doi: 10.1093/nar/gks1182 – volume: 14 start-page: R117 issue: 10 year: 2013 ident: 3890_CR31 publication-title: Genome Biol doi: 10.1186/gb-2013-14-10-r117 – volume: 12 start-page: 1349 issue: 7 year: 2012 ident: 3890_CR39 publication-title: Infect Genet Evol doi: 10.1016/j.meegid.2012.05.001 – volume: 23 start-page: 1644 issue: 9 year: 1995 ident: 3890_CR38 publication-title: Nucleic Acids Res doi: 10.1093/nar/23.9.1644 – volume: 116 start-page: 5507 issue: 25 year: 2010 ident: 3890_CR18 publication-title: Blood doi: 10.1182/blood-2010-05-283523 – volume: 30 start-page: 3813 issue: 35 year: 2011 ident: 3890_CR87 publication-title: Oncogene doi: 10.1038/onc.2011.99 – volume: 69 start-page: 446 issue: 1 year: 1995 ident: 3890_CR68 publication-title: J Virol doi: 10.1128/jvi.69.1.446-455.1995 – volume: 458 start-page: 719 issue: 7239 year: 2009 ident: 3890_CR75 publication-title: Nature doi: 10.1038/nature07943 – volume: 71 start-page: 439 issue: 2 year: 2002 ident: 3890_CR101 publication-title: Am J Hum Genet doi: 10.1086/341527 – volume: 4 start-page: 5 year: 2007 ident: 3890_CR50 publication-title: Retrovirology doi: 10.1186/1742-4690-4-5 – volume: 27 start-page: 264 issue: 3 year: 2009 ident: 3890_CR66 publication-title: Nat Biotechnol doi: 10.1038/nbt.1526 – volume: 86 start-page: 10524 issue: 19 year: 2012 ident: 3890_CR35 publication-title: J Virol doi: 10.1128/JVI.01077-12 – volume: 41 start-page: 563 issue: 5 year: 2009 ident: 3890_CR97 publication-title: Nature genetics doi: 10.1038/ng.368 – volume: 13 start-page: 2465 issue: 19 year: 1999 ident: 3890_CR64 publication-title: Genes Dev doi: 10.1101/gad.13.19.2465 – volume: 107 start-page: 21931 issue: 50 year: 2010 ident: 3890_CR26 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1016071107 – volume: 23 start-page: 111 issue: 2 year: 2012 ident: 3890_CR41 publication-title: Human Gene Therapy Methods doi: 10.1089/hgtb.2011.219 – volume: 68 start-page: 211 issue: 3 year: 2001 ident: 3890_CR81 publication-title: Breast Cancer Res Treat doi: 10.1023/A:1012265703669 – volume: 149 start-page: 1622 issue: 7 year: 2012 ident: 3890_CR93 publication-title: Cell doi: 10.1016/j.cell.2012.04.041 – volume: 12 start-page: 401 issue: 4 year: 2006 ident: 3890_CR15 publication-title: Nature medicine doi: 10.1038/nm1393 – volume: 53 start-page: 39 issue: 1 year: 2011 ident: 3890_CR40 publication-title: Methods doi: 10.1016/j.ymeth.2010.04.004 – volume: 78 start-page: 569 issue: 6 year: 2010 ident: 3890_CR55 publication-title: Kidney Int doi: 10.1038/ki.2010.176 – volume: 84 start-page: 3780 issue: 8 year: 2010 ident: 3890_CR54 publication-title: J Virol doi: 10.1128/JVI.02088-09 – volume: 6 start-page: e1001008 issue: 11 year: 2010 ident: 3890_CR23 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1001008 – volume: 138 start-page: 49 issue: 1 year: 1984 ident: 3890_CR1 publication-title: Virology doi: 10.1016/0042-6822(84)90146-6 – volume: 78 start-page: 335 issue: 4 year: 2013 ident: 3890_CR92 publication-title: Biochemistry – volume: 37 start-page: 1383 issue: 10 year: 2013 ident: 3890_CR52 publication-title: Leuk Res doi: 10.1016/j.leukres.2013.04.012 – volume: 24 start-page: 592 issue: 5 year: 2012 ident: 3890_CR6 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2012.08.006 – volume: 24 start-page: 119 issue: 2 year: 2013 ident: 3890_CR5 publication-title: Hum Gene Ther doi: 10.1089/hum.2012.203 – volume: 300 start-page: 1749 issue: 5626 year: 2003 ident: 3890_CR17 publication-title: Science doi: 10.1126/science.1083413 – volume: 18 start-page: 200 issue: 3 year: 1997 ident: 3890_CR84 publication-title: Genes Chromosomes Cancer doi: 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5 – volume: 108 start-page: 2419 issue: 12 year: 2013 ident: 3890_CR94 publication-title: Br J Cancer doi: 10.1038/bjc.2013.233 – volume: 60 start-page: 683 issue: 2 year: 1986 ident: 3890_CR16 publication-title: J Virol doi: 10.1128/jvi.60.2.683-692.1986 – volume: 69 start-page: 1379 issue: 6 year: 2007 ident: 3890_CR88 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2007.03.029 – volume: 488 start-page: 116 issue: 7409 year: 2012 ident: 3890_CR25 publication-title: Nature doi: 10.1038/nature11243 – volume: 364 start-page: 2181 issue: 9452 year: 2004 ident: 3890_CR10 publication-title: Lancet doi: 10.1016/S0140-6736(04)17590-9 – volume: 42 start-page: 4257 issue: 7 year: 2014 ident: 3890_CR22 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkt1399 – volume: 62 start-page: 147 issue: 2 year: 1999 ident: 3890_CR83 publication-title: Genomics doi: 10.1006/geno.1999.5952 – volume: 144 start-page: 327 issue: 3 year: 2011 ident: 3890_CR96 publication-title: Cell doi: 10.1016/j.cell.2011.01.024 – volume: 122 start-page: 1667 issue: 5 year: 2012 ident: 3890_CR44 publication-title: J Clin Invest doi: 10.1172/JCI62189 – volume: 292 start-page: 167 issue: 5819 year: 1981 ident: 3890_CR2 publication-title: Nature doi: 10.1038/292167a0 – volume: 3 start-page: 429 issue: 5 year: 2011 ident: 3890_CR4 publication-title: Viruses doi: 10.3390/v3050429 – volume: 120 start-page: 2981 issue: 15 year: 2012 ident: 3890_CR78 publication-title: Blood doi: 10.1182/blood-2012-02-409839 – volume: 5 start-page: e1000491 issue: 5 year: 2009 ident: 3890_CR71 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000491 – volume: 25 start-page: 1754 issue: 14 year: 2009 ident: 3890_CR100 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp324 – volume: 5 start-page: 886 issue: 4 year: 2013 ident: 3890_CR30 publication-title: Cell reports doi: 10.1016/j.celrep.2013.09.040 – volume: 8 start-page: e73974 issue: 9 year: 2013 ident: 3890_CR91 publication-title: PLoS One doi: 10.1371/journal.pone.0073974 – volume: 83 start-page: 8051 issue: 16 year: 2009 ident: 3890_CR7 publication-title: J Virol doi: 10.1128/JVI.00427-09 – volume: 32 start-page: 153 issue: 1 year: 2002 ident: 3890_CR36 publication-title: Nat Genet doi: 10.1038/ng950 – volume: 110 start-page: 12036 issue: 29 year: 2013 ident: 3890_CR29 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1307157110 – volume: 3 start-page: 89 issue: 2 year: 2011 ident: 3890_CR20 publication-title: EMBO Mol Med doi: 10.1002/emmm.201000108 – volume: 18 start-page: R195 issue: R2 year: 2009 ident: 3890_CR63 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddp409 – volume: 14 start-page: r106 issue: 9 year: 2013 ident: 3890_CR90 publication-title: Genome Biol doi: 10.1186/gb-2013-14-9-r106 – volume: 85 start-page: 6205 issue: 13 year: 2011 ident: 3890_CR43 publication-title: J Virol doi: 10.1128/JVI.00252-11 – volume: 13 start-page: 211 issue: 3 year: 2013 ident: 3890_CR3 publication-title: Curr Gene Ther doi: 10.2174/1566523211313030006 – volume: Chapter 18 start-page: Unit18 16 year: 2011 ident: 3890_CR89 publication-title: Curr Protoc Hum Genet – volume: 12 start-page: 656 issue: 4 year: 2002 ident: 3890_CR99 publication-title: Genome Res doi: 10.1101/gr.229202. Article published online before March 2002 – volume: 7 start-page: 562 issue: 3 year: 2012 ident: 3890_CR47 publication-title: Nat Protoc doi: 10.1038/nprot.2012.016 – volume: 107 start-page: 12992 issue: 29 year: 2010 ident: 3890_CR98 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1004139107 – volume: 288 start-page: 669 issue: 5466 year: 2000 ident: 3890_CR12 publication-title: Science doi: 10.1126/science.288.5466.669 – volume: 2 start-page: e00134 year: 2011 ident: 3890_CR46 publication-title: mBio doi: 10.1128/mBio.00134-11 – volume: 23 start-page: 917 issue: 6 year: 2013 ident: 3890_CR27 publication-title: Genome Res doi: 10.1101/gr.149674.112 – volume: 302 start-page: 415 issue: 5644 year: 2003 ident: 3890_CR72 publication-title: Science doi: 10.1126/science.1088547 – volume: 132 start-page: 797 issue: 4 year: 2005 ident: 3890_CR34 publication-title: Development doi: 10.1242/dev.01613 – volume: 31 start-page: 1139 issue: 5 year: 2013 ident: 3890_CR86 publication-title: Int J Mol Cell Med doi: 10.3892/ijmm.2013.1314 – volume: 40 start-page: 414 issue: 1 year: 2012 ident: 3890_CR42 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkr719 – volume: 74 start-page: 396 issue: 3 year: 2001 ident: 3890_CR62 publication-title: Genomics doi: 10.1006/geno.2001.6558 – volume: 27 start-page: 267 issue: 7 year: 2011 ident: 3890_CR59 publication-title: Trends Genet doi: 10.1016/j.tig.2011.04.002 – volume: 1 start-page: 27 issue: 1 year: 2012 ident: 3890_CR80 publication-title: Immunogastroenterology doi: 10.7178/ig.1.1.7 – volume: 85 start-page: 7393 issue: 14 year: 2011 ident: 3890_CR19 publication-title: J Virol doi: 10.1128/JVI.00635-11 – volume: 5 start-page: 4 year: 2008 ident: 3890_CR48 publication-title: Retrovirology doi: 10.1186/1742-4690-5-4 – volume: 73 start-page: 7599 issue: 9 year: 1999 ident: 3890_CR67 publication-title: J Virol doi: 10.1128/JVI.73.9.7599-7606.1999 – volume: 71 start-page: 882 issue: 10 year: 2012 ident: 3890_CR82 publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e31826bf704 – volume: 12 start-page: 283 issue: 4 year: 2011 ident: 3890_CR95 publication-title: Nat Rev Genet doi: 10.1038/nrg2957 – volume: 88 start-page: 4504 issue: 8 year: 2014 ident: 3890_CR24 publication-title: J Virol doi: 10.1128/JVI.00011-14 – volume: 21 start-page: 2181 issue: 12 year: 2011 ident: 3890_CR45 publication-title: Genome Res doi: 10.1101/gr.112763.110 – volume: 103 start-page: 18680 issue: 49 year: 2006 ident: 3890_CR49 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0609030103 |
| SSID | ssj0031808 |
| Score | 2.1753628 |
| Snippet | Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of... Background Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse... Doc number: 36 Abstract Background: Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for... Background: Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 36 |
| SubjectTerms | Animals Cancer Chromatin Cloning Complications and side effects Deoxyribonucleic acid DNA Epigenesis, Genetic Epigenetic inheritance Gene expression Genetic aspects Genetic Therapy - methods Genetic transcription Genetic Vectors - genetics Genomes Leukemia Virus, Murine - genetics Mice Mouse leukemia complex Mutagenesis Mutagenesis, Insertional - genetics Neoplasms - genetics Physiological aspects Principles Promoter Regions, Genetic Proviruses - genetics Retroviridae - genetics RNA sequencing Studies T-Lymphocytes - metabolism Transcription Initiation Site Transcriptional Activation - genetics Tumorigenesis Tumors Virus Integration - genetics |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Na51AEF_alEIvod81TcsWCu1lG1036-6phNIQesipgXeTdXdNH33q61MDIf98ZnS1sdCcRHZW1Pn6zTjOEPJRi6TMlBYss8AGIXjClJEps4UrXJYaAQestjiXZxfix-p4FRJubSirnGziYKhdYzFHfgSaqTnAA86_bv8wnBqFX1fDCI2H5BG2LsOSrmw1B1wgrrEK7XwSJY8AfHOG4eDQuk8uPNG_9viOQ1oWS97xPqdPyX6AjfRk5PMz8sDXz8njcZDk9Qtyc95c-Q3dTpnzljYlvTRVZdjOd5g1gGvSdY2f3ofcH-3QR00Wg-LfDWNuFohohRl4Tze-_-2rtaGwu28ZBO8gBo762jGAlJeedn3V7NqX5OL0-89vZyyMVWAWpxcwW-pCumNuYlto40pQvFIkwvI0417E1mlgrIsl1xzgoONcW5Wa1HhTgm9XRfqK7NVN7d8Q6lRaQghklUFcBnSlsPCiAEIkplBxFpEv0yvObeg5jqMvNvkQeyiZI09y5Amc5qmMyOd5w3Zst_F_0k_IsxwVEa5pTfifAO4MW1rlJyAwcsBPETlcUIIC2eXyxPU8KHCb_xW3iHyYl3EnFqXVvukHGq4FFuHeS4M9-yFoi8jrUZDmB-NgPKXIdESyhYjNBNj6e7lSr38NLcAhKldgSQ_uv_W35AngO4HFDok-JHvdrvfvAEN1xftBUW4BseMeVA priority: 102 providerName: ProQuest |
| Title | Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24886479 https://www.proquest.com/docview/1539285122 https://www.proquest.com/docview/1532942400 https://www.proquest.com/docview/1534837747 https://pubmed.ncbi.nlm.nih.gov/PMC4098794 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_eHYIv4rfVc4kg6EvObZptkweRVe44FlxEXdi3kibp3eK2PXe74uE_70z64VXOeyolk9BmZjK_mU5nCHmlRJgnUgmWGGCDEDxkUscRM5nNbBJpARfMtpjHpwsxW06Wf9sBtRu4vda1w35Si8366NePy_eg8O-8wsv4LYBqztDN8yX54j1yAGYpQS39JPpPCiC7vj1dT9zW-blmgYGJ-vegvmKphlmUV8zSyT1yt8WTdNoIwH1yy5UPyO2mw-TlQ_J7Xv10a3rRhdS3tMrpmS4KzTauxnACrElXJX6T90FBWqPx6o4Sir89NEFbIKIFhuYdXbvdd1esNIXZuy0Drx7kw1JXWgZY88zReldUm-0jsjg5_vbxlLX9FpjBtgbM5CqL7YTrscmUtjloZC5CYXiUcCfGxirguB3HXHHAiZZzZWSkI-10DkZfZtFjsl9WpXtKqJVRDr6RkRoBG9DlwsBGAbYIdSbHSUCOui1OTVuMHHtirFPvlMg4RZ6kyBO4TaM4IG_6CRdNHY7_k75GnqUoM7Cm0e2PBvBkWOsqnU4iFXtgFZDDASVolhkOd1xPO8FMwUIoDjCV84C87IdxJmarla7aeRquBGbn3kiDxfzBmwvIk0aQ-hfjcKrGIlEBSQYi1hNgTfDhSLk697XBwV2XcMQ-u_nNnpM7APwEZkGE6pDs15udewHgqs5GZC9ZJiNyMJ3Ovs7g-uF4_vnLyIcqRl6h_gAjfydF |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFS2QnBBvAkUMBIILqGJ4yb2AaECrba0rBBqpd5Sx3bKit1k2c2CKv6Jb2Qmj6VBoreeoshjK_a8J-MZgOdKhHkilfATg2gQgoe-1HHkm8xmNom0wAdlW4zi4ZH4eLx1vAa_u7swlFbZycRaUNvSUIx8EzlTcTQPOH87--5T1yj6u9q10GjIYt-d_USXbfFm7wPi9wXnuzuH74d-21XAN1S83ze5ymK7xXVgMqVtjnSXi1AYHiXcicBYhfuyQcwVR2vIcq6MjHSknc5RtckswnWvwLqI0JUZwPq7ndHnL53sRwYJZFtAKJTxJpr73CcHtC4WGPd0378a4JwK7KdnntN3uzfhRmuosu2Gsm7Bmituw9WmdeXZHfg1Kn-4CZt1sfoFK3N2qqdT7c9dRXEKXJONC_rZX0cbWUVasZNRjO5TNNFgBGJTivk7NnHLb2461gxnLxf-uLBIeJa5wvpoxJ46Vi2n5XxxF44u5cjvwaAoC_cAmJVRjk6XkZosQYTLhcGDQqMl1JkMEg9ed0ecmrbKOTXbmKS1tyPjlHCSEk7wNY1iD16tJsyaAh__B31JOEuJ9XFNo9sbDPhlVEQr3UYSjWuLzYONHiSyrOkPd1hPW5GxSP8SuAfPVsM0k9LgClcuaxiuBKX9XghDXQLQTfTgfkNIq41xFNexSJQHSY_EVgBUbLw_Uoy_1kXHRaAkyu6HF3_6U7g2PPx0kB7sjfYfwXW0LgWlWoRqAwbVfOkeowVXZU9atmFwctmc-gfb_V2l |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+principles+of+gamma-retroviral+insertional+transcription+activation+in+murine+leukemia+virus-induced+end-stage+tumors&rft.jtitle=Retrovirology&rft.au=Sokol%2C+Martin&rft.au=Wabl%2C+Matthias&rft.au=Ruiz%2C+Irene+Rius&rft.au=Pedersen%2C+Finn+Skou&rft.date=2014-05-19&rft.pub=BioMed+Central+Ltd&rft.issn=1742-4690&rft.eissn=1742-4690&rft.volume=11&rft_id=info:doi/10.1186%2F1742-4690-11-36&rft.externalDocID=A539671028 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-4690&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-4690&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-4690&client=summon |